Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2012

View Archived Issues

New potential analgesics disclosed by Novartis

GSK presents novel ITK/TSK inhibitors

Exelixis discovers new PI3Kdelta inhibitors

Novel inhibitors of neurotransmitter reuptake developed in Japan

Preclinical data support clinical testing of AVEO antibody

Addex discloses encouraging data on lead oral small molecule

Multitargeted antimitotic drug achieves tumor regression in vivo

Two new promising oncology programs presented

Regeneron Pharmaceuticals generates new anticancer antibody

Scientists describe analgesic effects of novel cannabinoid CB2 receptor agonists

First patient dosed in pivotal Arikace study

QRxPharma completes phase I trials of MoxDuo CR

New potential pancreatic cancer biomarker identified at H. Lee Moffitt Center

Vanda Pharmaceuticals acquires tachykinin NK1 receptor antagonist

Proteros and Eisai launch research collaboration

Merck & Co. gains worldwide rights to anticancer conjugate

UCB reports on phase III axial spondyloarthritis trial

Another milestone reached in phase IIa Cx-611 study

Novartis seeking approval in Japan of Glivec for new indication

Conformetrix enters first collaboration agreement

Dainippon Sumitomo Pharma seeks approval in Japan for Surepost in combination therapy

Eisai set to launch GABA(A) receptor agonist in Japan

Daiichi Sankyo launches Ranmark in Japan

Otsuka Pharmaceutical plans launch of new Abilify formulation

ThromboGenics resubmits BLA for ocriplasmin

Inspiration Biopharmaceuticals files for approval of rFIX product

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026